U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C16H25NO2.ClH
Molecular Weight 299.836
Optical Activity ( + / - )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TRAMADOL HYDROCHLORIDE

SMILES

Cl.COC1=CC=CC(=C1)[C@@]2(O)CCCC[C@@H]2CN(C)C

InChI

InChIKey=PPKXEPBICJTCRU-XMZRARIVSA-N
InChI=1S/C16H25NO2.ClH/c1-17(2)12-14-7-4-5-10-16(14,18)13-8-6-9-15(11-13)19-3;/h6,8-9,11,14,18H,4-5,7,10,12H2,1-3H3;1H/t14-,16+;/m1./s1

HIDE SMILES / InChI

Molecular Formula C16H25NO2
Molecular Weight 263.3752
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.drugs.com/tramadol.html | https://www.drugbank.ca/drugs/DB00193 | http://reference.medscape.com/drug/ultram-er-tramadol-343324 |

Tramadol (sold under the brand name Ultram) is a narcotic analgesic proposed for moderate to severe pain. Tramadol and its O-desmethyl metabolite (M1) are selective, weak OP3-receptor agonists. Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine, and noradrenaline is inhibited. The analgesic properties of Tramadol can be attributed to norepinephrine and serotonin reuptake blockade in the CNS, which inhibits pain transmission in the spinal cord. The (+) enantiomer has the higher affinity for the OP3 receptor and preferentially inhibits serotonin uptake and enhances serotonin release. The (-) enantiomer preferentially inhibits norepinephrine reuptake by stimulating alpha(2)-adrenergic receptors. Tramadol is used primarily to treat mild-severe pain, both acute and chronic. Its analgesic effects take about one hour to come into effect and 2 h to 4 h to peak after oral administration with an immediate-release formulation. On a dose-by-dose basis, tramadol has about one-tenth the potency of morphine and is approximately equally potent when compared to pethidine and codeine. The most common adverse effects of tramadol include nausea, dizziness, dry mouth, indigestion, abdominal pain, vertigo, vomiting, constipation, drowsiness, and headache. Compared to other opioids, respiratory depression and constipation are considered less of a problem with tramadol.

Originator

Sources: Oyo Yakuri (1973), 7, (7), 1087-95.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1300.0 nM [EC50]
14.0 nM [Ki]
9.4 nM [Ki]
1493.0 nM [IC50]
3861.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ULTRAM

Approved Use

Tramadol hydrochloride extended-release tablets are indicated for the management of moderate to moderately severe chronic pain in adults who require around-the-clock treatment of their pain for an extended period of time.

Launch Date

7.9418878E11
Primary
ULTRAM

Approved Use

Tramadol hydrochloride extended-release tablets are indicated for the management of moderate to moderately severe chronic pain in adults who require around-the-clock treatment of their pain for an extended period of time.

Launch Date

7.9418878E11
Primary
ULTRAM

Approved Use

Tramadol hydrochloride extended-release tablets are indicated for the management of moderate to moderately severe chronic pain in adults who require around-the-clock treatment of their pain for an extended period of time.

Launch Date

7.9418878E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
332 ng/mL
200 mg 1 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TRAMADOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
70 ng/mL
200 mg 1 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
O-DESMETHYLTRAMADOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
5678 ng × h/mL
200 mg 1 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TRAMADOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
1319 ng × h/mL
200 mg 1 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
O-DESMETHYLTRAMADOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
80%
200 mg 1 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TRAMADOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, 28
n = 8
Health Status: healthy
Age Group: 28
Sex: M+F
Population Size: 8
Sources:
Other AEs: Nausea, Vomiting...
Other AEs:
Nausea (75%)
Vomiting (50%)
Headache (25%)
Dizziness postural (25%)
Vertigo (25%)
Dizziness (12.5%)
Pruritus (37.5%)
Decreased appetite (25%)
Hot flush (12.5%)
Sources:
1500 mg single, oral (median)
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
unknown, 41
n = 359
Health Status: unknown
Age Group: 41
Sex: M+F
Population Size: 359
Sources:
Other AEs: Seizure, Nausea and vomiting...
Other AEs:
Seizure (14.5%)
Nausea and vomiting (53.5%)
Tachycardia (4.8%)
Hypertension (mild, 38.4%)
Arrhythmia (5.3%)
Sources:
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 1054
Health Status: unhealthy
Condition: osteoarthritis
Age Group: adult
Population Size: 1054
Sources:
Other AEs: Dry mouth, Sweating...
Other AEs:
Dry mouth (13.1%)
Sweating (6.7%)
Asthenia (8.6%)
Pruritus (7.3%)
Arthralgia (5%)
Headache (19%)
Nausea (25.1%)
Somnolence (16.1%)
Dizziness (13.6%)
Constipation (21.3%)
Vomiting (9.3%)
Anorexia (5.7%)
Insomnia (5%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Dizziness 12.5%
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, 28
n = 8
Health Status: healthy
Age Group: 28
Sex: M+F
Population Size: 8
Sources:
Hot flush 12.5%
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, 28
n = 8
Health Status: healthy
Age Group: 28
Sex: M+F
Population Size: 8
Sources:
Decreased appetite 25%
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, 28
n = 8
Health Status: healthy
Age Group: 28
Sex: M+F
Population Size: 8
Sources:
Dizziness postural 25%
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, 28
n = 8
Health Status: healthy
Age Group: 28
Sex: M+F
Population Size: 8
Sources:
Headache 25%
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, 28
n = 8
Health Status: healthy
Age Group: 28
Sex: M+F
Population Size: 8
Sources:
Vertigo 25%
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, 28
n = 8
Health Status: healthy
Age Group: 28
Sex: M+F
Population Size: 8
Sources:
Pruritus 37.5%
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, 28
n = 8
Health Status: healthy
Age Group: 28
Sex: M+F
Population Size: 8
Sources:
Vomiting 50%
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, 28
n = 8
Health Status: healthy
Age Group: 28
Sex: M+F
Population Size: 8
Sources:
Nausea 75%
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, 28
n = 8
Health Status: healthy
Age Group: 28
Sex: M+F
Population Size: 8
Sources:
Seizure 14.5%
1500 mg single, oral (median)
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
unknown, 41
n = 359
Health Status: unknown
Age Group: 41
Sex: M+F
Population Size: 359
Sources:
Tachycardia 4.8%
1500 mg single, oral (median)
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
unknown, 41
n = 359
Health Status: unknown
Age Group: 41
Sex: M+F
Population Size: 359
Sources:
Arrhythmia 5.3%
1500 mg single, oral (median)
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
unknown, 41
n = 359
Health Status: unknown
Age Group: 41
Sex: M+F
Population Size: 359
Sources:
Nausea and vomiting 53.5%
1500 mg single, oral (median)
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
unknown, 41
n = 359
Health Status: unknown
Age Group: 41
Sex: M+F
Population Size: 359
Sources:
Hypertension mild, 38.4%
1500 mg single, oral (median)
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
unknown, 41
n = 359
Health Status: unknown
Age Group: 41
Sex: M+F
Population Size: 359
Sources:
Dry mouth 13.1%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 1054
Health Status: unhealthy
Condition: osteoarthritis
Age Group: adult
Population Size: 1054
Sources:
Dizziness 13.6%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 1054
Health Status: unhealthy
Condition: osteoarthritis
Age Group: adult
Population Size: 1054
Sources:
Somnolence 16.1%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 1054
Health Status: unhealthy
Condition: osteoarthritis
Age Group: adult
Population Size: 1054
Sources:
Headache 19%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 1054
Health Status: unhealthy
Condition: osteoarthritis
Age Group: adult
Population Size: 1054
Sources:
Constipation 21.3%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 1054
Health Status: unhealthy
Condition: osteoarthritis
Age Group: adult
Population Size: 1054
Sources:
Nausea 25.1%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 1054
Health Status: unhealthy
Condition: osteoarthritis
Age Group: adult
Population Size: 1054
Sources:
Arthralgia 5%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 1054
Health Status: unhealthy
Condition: osteoarthritis
Age Group: adult
Population Size: 1054
Sources:
Insomnia 5%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 1054
Health Status: unhealthy
Condition: osteoarthritis
Age Group: adult
Population Size: 1054
Sources:
Anorexia 5.7%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 1054
Health Status: unhealthy
Condition: osteoarthritis
Age Group: adult
Population Size: 1054
Sources:
Sweating 6.7%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 1054
Health Status: unhealthy
Condition: osteoarthritis
Age Group: adult
Population Size: 1054
Sources:
Pruritus 7.3%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 1054
Health Status: unhealthy
Condition: osteoarthritis
Age Group: adult
Population Size: 1054
Sources:
Asthenia 8.6%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 1054
Health Status: unhealthy
Condition: osteoarthritis
Age Group: adult
Population Size: 1054
Sources:
Vomiting 9.3%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 1054
Health Status: unhealthy
Condition: osteoarthritis
Age Group: adult
Population Size: 1054
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
unlikely
yes
yes
likely (co-administration study)
Comment: Coadministration of quinidine, a selective inhibitor of CYP2D6, with tramadol ER resulted in a 50­ 60% increase in tramadol exposure; pharmacogenomic studies were also conducted: rapid conversion to active metabolite results in higher than expected serum M1 levels. Individuals who are ultra-rapid metabolizers should not use drug.
Page: 5.0
yes
likely (co-administration study)
Comment: The concomitant use of ULTRAM with cytochrome P450 3A4 inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir) or discontinuation of a cytochrome P450 3A4 inducer such as rifampin, carbamazepine, and phenytoin, may result in an increase in tramadol plasma concentrations; Concomitant administration of tramadol immediate-release tablets with cimetidine, a weak CPY3A4 inhibitor, does not result in clinically significant changes in tramadol pharmacokinetics;
Page: 5.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy.
2000 Mar-Apr
WHO Expert Committee on Drug Dependence. Thirty-second report.
2001
Postanaesthetic shivering: epidemiology, pathophysiology, and approaches to prevention and management.
2001
Single-dose dipyrone for acute postoperative pain.
2001
Use of remifentanil in combination with desflurane or propofol for ambulatory oral surgery.
2001
Intravenous tramadol compared to propacetamol for postoperative analgesia following thyroidectomy.
2001
A nonsurgical approach to low back pain.
2001 Apr
[Control of postoperative pain in heart surgery. Comparison of analgesics].
2001 Apr
A study of pain after laparoscopic gastric banding.
2001 Apr
[Factors affecting postoperative pain].
2001 Apr
Tramadol for postoperative shivering: a double-blind comparison with pethidine.
2001 Apr
[Clinical remission of an HLA B27-positive sacroiliitis on vegan diet].
2001 Aug
Pharmacology of oral combination analgesics: rational therapy for pain.
2001 Aug
Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes.
2001 Aug
Validation of a high-performance liquid chromatography method for tramadol and o-desmethyltramadol in human plasma using solid-phase extraction.
2001 Aug 15
Nefopam reduces thermal hypersensitivity in acute and postoperative pain models in the rat.
2001 Dec
Direct chiral assay of tramadol and detection of the phase II metabolite O-demethyl tramadol glucuronide in human urine using capillary electrophoresis with laser-induced native fluorescence detection.
2001 Dec 5
Fatality due to ingestion of tramadol alone.
2001 Feb 15
The effects of two single doses of tramadol on sleep: a randomized, cross-over trial in healthy volunteers.
2001 Jan
Slow-release tramadol for treatment of chronic malignant pain--an open multicenter trial.
2001 Jan
Using evidence from different sources: an example using paracetamol 1000 mg plus codeine 60 mg.
2001 Jan 10
Metabolism of the analgesic drug, tramadol hydrochloride, in rat and dog.
2001 Jul
Tramadol dependence with no history of substance abuse.
2001 Jun
Mania and tramadol-fluoxetine combination.
2001 Jun
Treatment of anorexia nervosa with tramadol.
2001 Jun
Treatment of refractory major depression with tramadol monotherapy.
2001 Mar
Treatment of severe pain from osteoarthritis with slow-release tramadol or dihydrocodeine in combination with NSAID's: a randomised study comparing analgesia, antinociception and gastrointestinal effects.
2001 Mar
Impact of experimentally-induced expectancy on the analgesic efficacy of tramadol in chronic pain patients: a 2 x 2 factorial, randomized, placebo-controlled, double-blind trial.
2001 Mar
Pharmacotherapy for nonmalignant pain.
2001 Mar 1
Efficacy and safety of dipyrone versus tramadol in the management of pain after hysterectomy: a randomized, double-blind, multicenter study.
2001 Mar-Apr
Role of tramadol in reducing pain on propofol injection.
2001 May
Effects of tramadol on T lymphocyte proliferation and natural killer cell activity in rats with sciatic constriction injury.
2001 May
A comparison of tramadol, amitriptyline, and meperidine for postepidural anesthetic shivering in parturients.
2001 Nov
Gas chromatographic method using nitrogen-phosphorus detection for the measurement of tramadol and its O-desmethyl metabolite in plasma and brain tissue of mice and rats.
2001 Nov 5
Acetaminophen, aspirin, or Ibuprofen in combination analgesic products.
2001 Nov-Dec
Urinary disorders on tramadol.
2001 Oct
Distribution of enantiomers of trans-tramadol and trans-O-demethyltramadol in central nervous system of rats.
2001 Oct
Ketorolac vs tramadol in the treatment of postoperative pain during maxillofacial surgery.
2001 Sep
Controlled release of tramadol hydrochloride from matrices prepared using glyceryl behenate.
2001 Sep
Tramadol and acetaminophen tablets for dental pain.
2001 Summer
New, non-NSAID alternative.
2002 Feb
Combination analgesic efficacy: individual patient data meta-analysis of single-dose oral tramadol plus acetaminophen in acute postoperative pain.
2002 Feb
[Recovery of lung function after laparoscopic cholecystectomy: the role of postoperative pain].
2002 Feb
In vivo microdialysis and conditioned place preference studies in rats are consistent with abuse potential of tramadol.
2002 Feb
Physical compatibility and in vivo evaluation of drug mixtures for subcutaneous infusion to cancer patients in palliative care.
2002 Jan
Meeting the therapeutic challenge of the patient with osteoarthritis.
2002 Jan-Feb
Patient reporting of potential adverse drug reactions: a methodological study.
2002 Mar
Tramadol has no effect on cortical renal blood flow--despite increased serum catecholamine levels--in anesthetized rats: implications for analgesia in renal insufficiency.
2002 Mar
Patents

Sample Use Guides

Chronic: 25 mg PO every morning initially; increased by 25-50 mg/day every 3 days up to 50-100 mg PO q4-6hr PRN; not to exceed 400 mg/day Acute: 50-100 mg PO q4-6hr PRN; not to exceed 400 mg/day
Route of Administration: Oral
A malignancy of A549 and PC-9 cells was detected after treatment of 2 μM tramadol for different time (0, 7, 14, or 28 d). The effect of tramadol on the invasion of A549 and PC-9 cells was performed using transwell chambers (6.5 mm diameter and 8 μm pore size; Millipore, Billerica, MA, USA). After treated with 2 μM tramadol for various time, cells were plated onto the Matrigel-coated upper part of the transwell chamber, fetal bovine serum (FBS) medium (20%) was added to the lower wells as a chemoattractant. 48 hours later, non-invading cells were removed, the invaded cells were fixed with 4% paraformaldehyde for 30 min and stained with 1% crystal violet for 30 min. The number of stained cells on the undersurface of the polycarbonate membranes was then counted visually in five random image fields at 200 × magnifications using a microscope (Olympus, Lake Success, NY, USA).
Substance Class Chemical
Created
by admin
on Wed Jul 05 22:43:14 UTC 2023
Edited
by admin
on Wed Jul 05 22:43:14 UTC 2023
Record UNII
9N7R477WCK
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TRAMADOL HYDROCHLORIDE
EP   HSDB   JAN   MART.   MI   ORANGE BOOK   USAN   USP   VANDF   WHO-DD  
USAN  
Official Name English
ZERTANE
Brand Name English
TRAMADOL HYDROCHLORIDE [VANDF]
Common Name English
ULTRAM
Brand Name English
CG-315
Code English
TRADONAL
Brand Name English
TRAMADOL HYDROCHLORIDE [MART.]
Common Name English
NSC-759105
Code English
TRAMADOL HYDROCHLORIDE CIV
USP-RS  
Common Name English
TRAMADOL HCL
Common Name English
CONTRAMAL
Brand Name English
(±)-CIS-2-((DIMETHYLAMINO)METHYL)-1-(M-METHOXYPHENYL)CYCLOHEXANOL HYDROCHLORIDE
Common Name English
TRAMADOL HYDROCHLORIDE [USAN]
Common Name English
TRAMADOL HYDROCHLORIDE CIV [USP-RS]
Common Name English
TRAMADOL HYDROCHLORIDE [JAN]
Common Name English
CONZIP
Brand Name English
TRAMADOL HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
TRAMADOL HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
NIH-10969
Code English
ULTRACET COMPONENT TRAMADOL HYDROCHLORIDE
Common Name English
TRAMADOL HYDROCHLORIDE [MI]
Common Name English
ZYDOL
Brand Name English
AMADOL
Brand Name English
U-26,225A
Code English
U-26225A
Code English
TRAMADOL HYDROCHLORIDE [HSDB]
Common Name English
ZAMUDOL
Brand Name English
QDOLO
Brand Name English
TRAMAL
Brand Name English
Tramadol hydrochloride [WHO-DD]
Common Name English
TRAMADOL HYDROCHLORIDE COMPONENT OF ULTRACET
Common Name English
TRAMADOL HYDROCHLORIDE [ORANGE BOOK]
Common Name English
CYCLOHEXANOL, 2-((DIMETHYLAMINO)METHYL)-1-(3-METHOXYPHENYL)-, HYDROCHLORIDE, (1R,2R)-REL-
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C241
Created by admin on Wed Jul 05 22:43:14 UTC 2023 , Edited by admin on Wed Jul 05 22:43:14 UTC 2023
DEA NO. 9278
Created by admin on Wed Jul 05 22:43:14 UTC 2023 , Edited by admin on Wed Jul 05 22:43:14 UTC 2023
EU-Orphan Drug Tramadol hydrochloride
Created by admin on Wed Jul 05 22:43:14 UTC 2023 , Edited by admin on Wed Jul 05 22:43:14 UTC 2023
FDA ORPHAN DRUG 192804
Created by admin on Wed Jul 05 22:43:14 UTC 2023 , Edited by admin on Wed Jul 05 22:43:14 UTC 2023
FDA ORPHAN DRUG 197004
Created by admin on Wed Jul 05 22:43:14 UTC 2023 , Edited by admin on Wed Jul 05 22:43:14 UTC 2023
Code System Code Type Description
MERCK INDEX
M10996
Created by admin on Wed Jul 05 22:43:14 UTC 2023 , Edited by admin on Wed Jul 05 22:43:14 UTC 2023
PRIMARY Merck Index
SMS_ID
100000093275
Created by admin on Wed Jul 05 22:43:14 UTC 2023 , Edited by admin on Wed Jul 05 22:43:14 UTC 2023
PRIMARY
ChEMBL
CHEMBL1237044
Created by admin on Wed Jul 05 22:43:14 UTC 2023 , Edited by admin on Wed Jul 05 22:43:14 UTC 2023
PRIMARY
NCI_THESAURUS
C29508
Created by admin on Wed Jul 05 22:43:14 UTC 2023 , Edited by admin on Wed Jul 05 22:43:14 UTC 2023
PRIMARY
CAS
53611-16-8
Created by admin on Wed Jul 05 22:43:14 UTC 2023 , Edited by admin on Wed Jul 05 22:43:14 UTC 2023
SUPERSEDED
EVMPD
SUB04927MIG
Created by admin on Wed Jul 05 22:43:14 UTC 2023 , Edited by admin on Wed Jul 05 22:43:14 UTC 2023
PRIMARY
CHEBI
9648
Created by admin on Wed Jul 05 22:43:14 UTC 2023 , Edited by admin on Wed Jul 05 22:43:14 UTC 2023
PRIMARY
DRUG BANK
DBSALT000181
Created by admin on Wed Jul 05 22:43:14 UTC 2023 , Edited by admin on Wed Jul 05 22:43:14 UTC 2023
PRIMARY
DAILYMED
9N7R477WCK
Created by admin on Wed Jul 05 22:43:14 UTC 2023 , Edited by admin on Wed Jul 05 22:43:14 UTC 2023
PRIMARY
PUBCHEM
63013
Created by admin on Wed Jul 05 22:43:14 UTC 2023 , Edited by admin on Wed Jul 05 22:43:14 UTC 2023
PRIMARY
RXCUI
82110
Created by admin on Wed Jul 05 22:43:14 UTC 2023 , Edited by admin on Wed Jul 05 22:43:14 UTC 2023
PRIMARY RxNorm
CAS
194602-08-9
Created by admin on Wed Jul 05 22:43:14 UTC 2023 , Edited by admin on Wed Jul 05 22:43:14 UTC 2023
SUPERSEDED
CAS
2914-78-5
Created by admin on Wed Jul 05 22:43:14 UTC 2023 , Edited by admin on Wed Jul 05 22:43:14 UTC 2023
NON-SPECIFIC STEREOCHEMISTRY
CHEBI
32250
Created by admin on Wed Jul 05 22:43:14 UTC 2023 , Edited by admin on Wed Jul 05 22:43:14 UTC 2023
PRIMARY
CAS
22204-88-2
Created by admin on Wed Jul 05 22:43:14 UTC 2023 , Edited by admin on Wed Jul 05 22:43:14 UTC 2023
SUPERSEDED
CAS
36282-47-0
Created by admin on Wed Jul 05 22:43:14 UTC 2023 , Edited by admin on Wed Jul 05 22:43:14 UTC 2023
PRIMARY
ECHA (EC/EINECS)
252-950-2
Created by admin on Wed Jul 05 22:43:14 UTC 2023 , Edited by admin on Wed Jul 05 22:43:14 UTC 2023
PRIMARY
FDA UNII
9N7R477WCK
Created by admin on Wed Jul 05 22:43:14 UTC 2023 , Edited by admin on Wed Jul 05 22:43:14 UTC 2023
PRIMARY
RS_ITEM_NUM
1672600
Created by admin on Wed Jul 05 22:43:14 UTC 2023 , Edited by admin on Wed Jul 05 22:43:14 UTC 2023
PRIMARY
NSC
759105
Created by admin on Wed Jul 05 22:43:14 UTC 2023 , Edited by admin on Wed Jul 05 22:43:14 UTC 2023
PRIMARY
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
PARENT -> SALT/SOLVATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
Related Record Type Details
IMPURITY -> PARENT
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
TLC, ASSUMED FREE BASE
CHROMATOGRAPHIC PURITY (TLC)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
EP
Related Record Type Details
ACTIVE MOIETY